Non-alcoholic fatty liver disease is present in 15–25% of the general population. The fundamental derangement in non-alcoholic fatty liver disease is insulin resistance, a key component of the metabolic syndrome, which includes type 2 diabetes mellitus, dyslipidemia, hypertension, and obesity. The natural history of non-alcoholic fatty liver disease is not always benign, its causality for chronic liver disease and cirrhosis is well known in clinical practice and sometimes it is accompanied by hepatocellular carcinoma. Non-alcoholic fatty liver disease is likely to be associated with increased cardiovascular disease risk, and raises the possibility that non-alcoholic fatty liver disease may be not only a marker but also an early mediator of atherosclerosis. Therapy is currently directed at treating components of the metabolic syndrome which may also beneficial for the liver.
Adams, L. A., Lindor, K. D.: Nonalcoholic fatty liver disease. Ann. Epidemiol., 2007, 17 , 863–869.
Lindor K. D. , 'Nonalcoholic fatty liver disease ' (2007 ) 17 Ann. Epidemiol. : 863 -869 .
Akbar, D. H., Kawther, A. H.: Non-alcoholic fatty liver disease and metabolic syndrome: what we know and what we dont’t know. Med. Sci. Monit., 2006, 12 , 23–26.
Kawther A. H. , 'Non-alcoholic fatty liver disease and metabolic syndrome: what we know and what we dont’t know ' (2006 ) 12 Med. Sci. Monit. : 23 -26 .
Targher, G., Bertolini, L., Padovani, R. et al.: Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. Diabet. Care, 2007, 30 , 1212–1218.
Padovani R. , 'Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients ' (2007 ) 30 Diabet. Care : 1212 -1218 .
Fraenkel, E., Takács, R., Hamvas, J. et al.: A nem alkoholos zsírmáj és az epekövesség együttes előfordulásának megfigyelése. (Common occurrence of non-alcoholic fatty liver and cholecystolithiasis.) (In Hungarian). Orv. Hetil., 2007, 148 , 793–798.
Hamvas J. , 'A nem alkoholos zsírmáj és az epekövesség együttes előfordulásának megfigyelése. (Common occurrence of non-alcoholic fatty liver and cholecystolithiasis.) (In Hungarian) ' (2007 ) 148 Orv. Hetil. : 793 -798 .
Bogdanova, K., Poczatkova, H., Uherkova, L. et al.: Non-alcoholic fatty liver disease (NAFLD) – a novel common aspect of the metabolic syndrome. Biomed. Pap. Med. Fac. Univ. Papacky Olomouc Czech. Repub., 2006, 150 , 101–104.
Uherkova L. , 'Non-alcoholic fatty liver disease (NAFLD) – a novel common aspect of the metabolic syndrome ' (2006 ) 150 Biomed. Pap. Med. Fac. Univ. Papacky Olomouc Czech. Repub. : 101 -104 .
Fehér, J., Németh, E., Lengyel, G.: Non-alcoholic steatohepatitis (NASH) – is it a part of the metabolic syndrome? Arch. Med. Sci., 2005, 1 , 37–47.
Lengyel G. , 'Non-alcoholic steatohepatitis (NASH) – is it a part of the metabolic syndrome? ' (2005 ) 1 Arch. Med. Sci. : 37 -47 .
Musso, G., Gambino, R., Bo, S. et al.: Should nonalcoholic fatty liver disease be included in the definition of metabolic syndrome? Diabet. Care, 2008, 31 , 562–568.
Bo S. , 'Should nonalcoholic fatty liver disease be included in the definition of metabolic syndrome? ' (2008 ) 31 Diabet. Care : 562 -568 .
Eiszrich, Á., Fehér, J.: Gyermekkori zsírmáj. (Fatty liver in childhood.) (In Hungarian). Orv., Hetil., 2007, 148 , 2461–2468.
Fehér J. , 'Gyermekkori zsírmáj. (Fatty liver in childhood.) (In Hungarian) ' (2007 ) 148 Orv., Hetil. : 2461 -2468 .
Day, C. P., James, O. F. W.: Steatohepatitis: a tale of two ’hits’. Gastroenterology, 1998, 114 , 842–845.
James O. F. W. , 'Steatohepatitis: a tale of two ’hits’ ' (1998 ) 114 Gastroenterology : 842 -845 .
Riley, P., O’Donohue, J., Crook, M.: A growing burden: the pathogenesis, investigation and management of non-alcoholic fatty liver disease. J. Clin. Pathol., 2007, 60 , 1384–1391.
Crook M. , 'A growing burden: the pathogenesis, investigation and management of non-alcoholic fatty liver disease ' (2007 ) 60 J. Clin. Pathol. : 1384 -1391 .
Parekh, S., Anania, F. A.: Abnormal lipid and glucose metabolism in obesity: Implications for nonalcoholic fatty liver disease. Gastroenterology, 2007, 132 , 2191–2207.
Anania F. A. , 'Abnormal lipid and glucose metabolism in obesity: Implications for nonalcoholic fatty liver disease ' (2007 ) 132 Gastroenterology : 2191 -2207 .
Tamura, S., Shimomura, I.: Contribution of adipose tissue and de novo lipogenesis to nonalcoholic fatty liver disease. J. Clin. Invest., 2005, 115 , 1139–1142.
Shimomura I. , 'Contribution of adipose tissue and de novo lipogenesis to nonalcoholic fatty liver disease ' (2005 ) 115 J. Clin. Invest. : 1139 -1142 .
Browning, J. D., Horton, J. D.: Molecular mediators of hepatic steatosis and liver injury. J. Clin. Invest., 2004, 114 , 147–152.
Horton J. D. , 'Molecular mediators of hepatic steatosis and liver injury ' (2004 ) 114 J. Clin. Invest. : 147 -152 .
Charlton, M., Sreekumar, R., Rasmussen, D. et al.: Apolipoprotein synthesis in nonalcoholic steatohepatitis. Hepatology, 2002, 35 , 898–904.
Rasmussen D. , 'Apolipoprotein synthesis in nonalcoholic steatohepatitis ' (2002 ) 35 Hepatology : 898 -904 .
Cummings, M. H., Watts, G. F., Umpleby, A. M. et al.: Acute hyperinsulinemia decreases the hepatic secretion of very-low-density lipoprotein apolipoprotein B-100 in NIDDM. Diabetes, 1995, 44 , 1059–1065.
Umpleby A. M. , 'Acute hyperinsulinemia decreases the hepatic secretion of very-low-density lipoprotein apolipoprotein B-100 in NIDDM ' (1995 ) 44 Diabetes : 1059 -1065 .
Gaemers, I. C., Groen, A. K.: New insights in the pathogenesis of non-alcoholic fatty liver disease. Curr. Opin. Lipidol., 2006, 17 , 268–273.
Groen A. K. , 'New insights in the pathogenesis of non-alcoholic fatty liver disease ' (2006 ) 17 Curr. Opin. Lipidol. : 268 -273 .
Wolfrum, C., Asilmaz, E., Luca, E. et al.: Foxa2 regulates lipid metabolism and ketogenesis in the liver during fasting and in diabetes. Nature, 2004, 432 , 1027–1032.
Luca E. , 'Foxa2 regulates lipid metabolism and ketogenesis in the liver during fasting and in diabetes ' (2004 ) 432 Nature : 1027 -1032 .
Coppack, S. W.: Pro-inflammatory cytokines and adipose tissue. Proc. Nutr. Soc., 2001, 60 , 349–356.
Coppack S. W. , 'Pro-inflammatory cytokines and adipose tissue ' (2001 ) 60 Proc. Nutr. Soc. : 349 -356 .
Saxena, N. K., Ikeda, K., Rockey, D. C. et al.: Leptin in hepatic fibrosis: evidence for increased collagen production in stellate cells and lean littermates of ob/ob mice. Hepatology, 2002, 35 , 762–771.
Rockey D. C. , 'Leptin in hepatic fibrosis: evidence for increased collagen production in stellate cells and lean littermates of ob/ob mice ' (2002 ) 35 Hepatology : 762 -771 .
Hui, J. M., Hodge, A., Farrell, G. C. et al.: Beyond insulin resistance in NASH: TNF-α or adiponectin? Hepatology, 2004, 40 , 46–54.
Farrell G. C. , 'Beyond insulin resistance in NASH: TNF-α or adiponectin? ' (2004 ) 40 Hepatology : 46 -54 .
Pagano, C., Soardo, G., Pilon, C. et al.: Increased serum resistin in nonalcoholic fatty liver disease is related to liver disease severity and not to insulin resistance. J. Clin. Endocrinol. Metab., 2006, 91 , 1081–1086.
Pilon C. , 'Increased serum resistin in nonalcoholic fatty liver disease is related to liver disease severity and not to insulin resistance ' (2006 ) 91 J. Clin. Endocrinol. Metab. : 1081 -1086 .
Perseghin, G., Lattuada, G., De Cobelli, F. et al.: Serum resistin and hepatic fat content in non-diabetic individuals. J. Clin. Endocrinol. Metab., 2006, 91 , 5122–5125.
Cobelli F. , 'Serum resistin and hepatic fat content in non-diabetic individuals ' (2006 ) 91 J. Clin. Endocrinol. Metab. : 5122 -5125 .
Graham, T. E., Yang, Q., Blüher, M. et al.: Retinol-binding protein 4 and insulin resistance in lean, obese, and diabetic subjects. N. Engl. J. Med., 2006, 354 , 2552–2563.
Blüher M. , 'Retinol-binding protein 4 and insulin resistance in lean, obese, and diabetic subjects ' (2006 ) 354 N. Engl. J. Med. : 2552 -2563 .
Neuschwander-Tetri, B. A.: Fatty liver and metabolic syndrome. Curr. Opin. Gastroenterol., 2007, 23 , 193–198.
Neuschwander-Tetri B. A. , 'Fatty liver and metabolic syndrome ' (2007 ) 23 Curr. Opin. Gastroenterol. : 193 -198 .
Fracanzani, A. L., Burdick, L., Rasselli, S. et al.: Risk of early atherosclerosis evaluated by carotid artery intima-media thickness in patients with non alcoholic fatty liver disease: a case-control study. Hepatology, 2005, 42 , 610A–1A.
Rasselli S. , 'Risk of early atherosclerosis evaluated by carotid artery intima-media thickness in patients with non alcoholic fatty liver disease: a case-control study ' (2005 ) 42 Hepatology : 610A -1A .
Villanova, N., Moscatiello, S., Ramilli, S. et al.: Endothelial dysfunction and cardiovascular risk profile in nonalcoholic fatty liver disease. Hepatology, 2005, 42 , 473–478.
Ramilli S. , 'Endothelial dysfunction and cardiovascular risk profile in nonalcoholic fatty liver disease ' (2005 ) 42 Hepatology : 473 -478 .
Targher, G., Bertolini, L., Padovani, R. et al.: Increased prevalence of cardiovascular disease among type 2 diabetic patients with non-alcoholic fatty liver disease. Diabet. Med., 2006, 23 , 403–409.
Padovani R. , 'Increased prevalence of cardiovascular disease among type 2 diabetic patients with non-alcoholic fatty liver disease ' (2006 ) 23 Diabet. Med. : 403 -409 .
Lin, Y. C., Lo, H. M., Chen, J. D.: Sonographic fatty liver, overweight and ischemic heart disease. World J. Gastroenterol., 2005, 11 , 4838–4842.
Chen J. D. , 'Sonographic fatty liver, overweight and ischemic heart disease ' (2005 ) 11 World J. Gastroenterol. : 4838 -4842 .
Wannamethee, G., Ebrahim, S., Shaper, A. G. et al.: Gamma-glutamyltransferase: determinants and association with mortality from ischaemic heart disease and all causes. Am. J. Epidemiol., 1995, 142 , 699–708.
Shaper A. G. , 'Gamma-glutamyltransferase: determinants and association with mortality from ischaemic heart disease and all causes ' (1995 ) 142 Am. J. Epidemiol. : 699 -708 .
Ruttmann, E., Brant, L. J., Concin, H. et al.: Gamma-glutamyltransferase as a risk factor for cardiovascular disease mortality: an epidemiological investigation in a cohort of 163,944 Austrian adults. Circulation, 2005, 112 , 2130–2137.
Concin H. , 'Gamma-glutamyltransferase as a risk factor for cardiovascular disease mortality: an epidemiological investigation in a cohort of 163,944 Austrian adults ' (2005 ) 112 Circulation : 2130 -2137 .
Ioannou, G. N., Weiss, N. S., Boyko, E. J. et al.: Elevated serum alanine aminotransferase activity and calculated risk of coronary heart disease in the United States. Hepatology, 2006, 43 , 1145–1151.
Boyko E. J. , 'Elevated serum alanine aminotransferase activity and calculated risk of coronary heart disease in the United States ' (2006 ) 43 Hepatology : 1145 -1151 .
Fehér, J., Lengyel, G.: A new approach to drug therapy in non-alcoholic steatohepatitis (NASH). J. Int. Med. Res., 2003, 31 , 537–551.
Lengyel G. , 'A new approach to drug therapy in non-alcoholic steatohepatitis (NASH) ' (2003 ) 31 J. Int. Med. Res. : 537 -551 .
Watts, G. F., Gan, S. K.: Nutrition and metabolism: non-alcoholic fatty liver disease – pathogenesis, cardiovascular risk and therapy. Curr. Opin. Lipidol., 2008, 19 , 92–94.
Gan S. K. , 'Nutrition and metabolism: non-alcoholic fatty liver disease – pathogenesis, cardiovascular risk and therapy ' (2008 ) 19 Curr. Opin. Lipidol. : 92 -94 .
Bende, J., Csiszár, M., Ursu, M.: Modern sebészi lehetőségek a nagyfokú elhízás kezelésében. (Modern surgical possibilities in the treatment of morbid obesity.) (In Hungarian). Orv. Hetil., 2003, 100 , 2459–2463.
Ursu M. , 'Modern sebészi lehetőségek a nagyfokú elhízás kezelésében. (Modern surgical possibilities in the treatment of morbid obesity.) (In Hungarian) ' (2003 ) 100 Orv. Hetil. : 2459 -2463 .
De Alwis, N. M. W., Day, C., P.: Non-alcoholic fatty liver disease: The mist gradually clears. J. Hepatol., 2008, 48 , S104–S112.
Day C., P. , 'Non-alcoholic fatty liver disease: The mist gradually clears ' (2008 ) 48 J. Hepatol. : S104 -S112 .
Hirose, A., Ono, M., Saibara, T. et al.: Angiotensin II type 1 receptor blocker inhibits fibrosis in rat nonalcoholic steatohepatitis. Hepatology, 2007, 45 , 1375–1381.
Saibara T. , 'Angiotensin II type 1 receptor blocker inhibits fibrosis in rat nonalcoholic steatohepatitis ' (2007 ) 45 Hepatology : 1375 -1381 .
Fehér, J., Sulyok, S., Várnai, K. et al.: The effect of a new synthetic dihydroquinoline type antioxidant in experimental atherosclerosis. Lipid Res., 1984, 4 , 20–26.
Várnai K. , 'The effect of a new synthetic dihydroquinoline type antioxidant in experimental atherosclerosis ' (1984 ) 4 Lipid Res. : 20 -26 .
Lindor, K., Kowdley, K., Heathcote, E. et al.: Ursodeoxycholic acid for treatment of non alcoholic steatohepatitis: results of a randomized trial. Hepatology, 2004, 39 , 770–778.
Heathcote E. , 'Ursodeoxycholic acid for treatment of non alcoholic steatohepatitis: results of a randomized trial ' (2004 ) 39 Hepatology : 770 -778 .
Dufour, J., Oneta, C., Gonvers, J. et al.: Swiss Association for the Study of the Liver: randomized placebo controlled trial of ursodeoxycholic acid with vitamin E in nonalcoholic steatohepatitis. Clin. Gastroenterol. Hepatol., 2006, 4 , 1537–1543.
Gonvers J. , 'Swiss Association for the Study of the Liver: randomized placebo controlled trial of ursodeoxycholic acid with vitamin E in nonalcoholic steatohepatitis ' (2006 ) 4 Clin. Gastroenterol. Hepatol. : 1537 -1543 .
Satapathy, S., Sakhuja, P., Malhotra, V. et al.: Benefical effects of pentoxyfilline on hepatic steatosis, fibrosis and necroinflammation in patients with non alcoholic steatohepatitis. J. Gastroenterol. Hepatol., 2007, 22 , 634–638.
Malhotra V. , 'Benefical effects of pentoxyfilline on hepatic steatosis, fibrosis and necroinflammation in patients with non alcoholic steatohepatitis ' (2007 ) 22 J. Gastroenterol. Hepatol. : 634 -638 .
SOng, J., Younossi, Z., Reddy, V. et al.: Cryptogenic cirrhosis and post-transplantation nonalcoholic fatty liver disease. Liver Transpl., 2001, 7 , 797–801.
Reddy V. , 'Cryptogenic cirrhosis and post-transplantation nonalcoholic fatty liver disease ' (2001 ) 7 Liver Transpl. : 797 -801 .